Early Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunction

Basit Öğe Kaydı
dc.authoridArda, Ersan/0000-0002-5430-6561
dc.authoridTas, Tuncay/0000-0002-3816-4874
dc.authoridCakiroglu, Basri/0000-0001-5337-5226
dc.authorwosidArda, Ersan/L-7357-2016
dc.authorwosidonuk, özkan/AAD-8784-2020
dc.authorwosidCakiroglu, Basri/M-5101-2018
dc.contributor.authorTas, Tuncay
dc.contributor.authorCakiroglu, Basri
dc.contributor.authorArda, Ersan
dc.contributor.authorOnuk, Ozkan
dc.contributor.authorNuhoglu, Baris
dc.date.accessioned2024-06-12T11:00:33Z
dc.date.available2024-06-12T11:00:33Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: Platelet-rich plasma (PRP) is useful in the treatment of different conditions and diseases as it contains concentrated levels of many growth factors. Aim: The aim of this study was to investigate the effectiveness of autologous PRP application in the treatment of erectile dysfunction (ED) in patients with metabolic syndrome. Methods: In this prospective study conducted in June 2019, 31 patients with ED were included. The International Index of Erectile Function-Erectile Function domain (IIEF-EF) questionnaires were used to evaluate erectile function (EF). After administering the intracavernous autologous PRP 3 times with an interval of 15 days, IIEF-EFs were evaluated 1, 3, and 6 months later. Main Outcome Measure: IIEF in the 1st, 3rd, and 6th months and adverse events. Results: While the mean IIEF-EF was 18 before the application, the mean IIEF-EF was 20 in the first, third, and sixth months after the procedure (P < .001). However, even though IIEF-EF values increased numerically, median value remained within the mild-moderate classification (scores between 17 and 21). Postprocedure sexual satisfaction scores were significantly higher than preprocedure values (8 vs 6, respectively; P 1/4 .002). In the first follow-up of a patient after the 3rd injection, a 4-mm diameter fibrotic plaque was observed on the ventral side in the middle of the penis shaft. Conclusion: In conclusion, our findings suggest that larger studies as well as placebo-controlled studies are needed to add PRP to the treatment protocol in ED. Copyright (C) 2021, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.en_US
dc.identifier.doi10.1016/j.esxm.2020.100313
dc.identifier.issn2050-1161
dc.identifier.issue2en_US
dc.identifier.pmid33529814en_US
dc.identifier.scopus2-s2.0-85100066869en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.esxm.2020.100313
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20881
dc.identifier.volume9en_US
dc.identifier.wosWOS:000640009400012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofSexual Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectErectile Dysfunctionen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectPlatelet-Rich Plasmaen_US
dc.subjectInternational Index Of Erectile Function-Erectile Function Domainen_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectInternational Indexen_US
dc.subjectHealthen_US
dc.subjectAssociationen_US
dc.subjectObesityen_US
dc.subjectDeficiencyen_US
dc.subjectMechanismsen_US
dc.subjectInjectionen_US
dc.subjectFibrosisen_US
dc.subjectVersionen_US
dc.titleEarly Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu